Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pancrelipase MT withdrawal study in cystic fibrosis-related exocrine pancreatic insufficiency
2015-001219-11Phase 3
- Sponsor
- Johnson & Johnson
- Start
- Mar 2015
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) and exocrine pancreatic insufficiency (EPI) comparing PANCREASE MT with Placebo (2 arms). Primary endpoint: Change in coefficient of fat absorption.
02
Drugs
Pancrelipase protease
03
Conditions
cystic fibrosis (CF)exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on 2015-001219-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001219-11.